Abstract Number: 0778 • ACR Convergence 2023
The Effect of Probiotic Modulation of Enteral Dysbiosis on Disease Activity in Patients with Psoriatic Arthritis – A Randomized Controlled Trial
Background/Purpose: Psoriatic Arthritis (PsA) is a painful disease of the joints and spine. Recent studies have described enteric dysbiosis as a possible pathological mechanism in…Abstract Number: 1388 • ACR Convergence 2023
Pain Mechanisms in Psoriatic Arthritis: Differentiating Inflammation Related Pain in Enthesitis Using Ultrasound, in Comparison to Functional MRI
Background/Purpose: Approximately 50% of PsA patients have persistent pain despite a well‐controlled inflammatory state, which has been attributed to non‐nociceptive pain and central sensitization. Enthesitis…Abstract Number: 1426 • ACR Convergence 2023
Distinct Treatment Response Trajectories in Patients with Psoriatic Arthritis Receiving Tofacitinib
Background/Purpose: PsA is a heterogeneous disease, and identifying clinical phenotypes may assist clinical decision making. Patients (pts) treated with advanced therapies demonstrate varying treatment responses.…Abstract Number: 1640 • ACR Convergence 2023
Psoriatic Disease Associated with Neuroconnectivity Alterations in the Default Mode Network
Background/Purpose: Despite significant advances in psoriatic disease (PsD) therapeutics, treatment response remains suboptimal. Even in patients with psoriatic arthritis (PSA) that achieve seemingly controlled inflammation,…Abstract Number: 1787 • ACR Convergence 2023
Regulatory Role of JAK-1/TYK2 Signaling on the Pannus Formation: Novel Mechanisms for JAK Inhibitors in Psoriatic Disease
Background/Purpose: In psoriatic arthritis (PsA) aberrant activation/migration of specific T cell subpopulations (Th17/Th9/MAIT cells) in the joint synovium induce synovial inflammation and pannus formation. Several…Abstract Number: 2232 • ACR Convergence 2023
Guselkumab, an IL-23p19 Subunit–specific Monoclonal Antibody, Is Able to Bind CD64+ Myeloid Cells, Potently Neutralize IL-23 Produced from the Cells, and Mediate Internalization of IL-23
Background/Purpose: Monoclonal antibodies (mAbs) targeting the interleukin (IL)-23p19 subunit are effective in treating psoriatic disease; however, their molecular attributes may translate to differences in clinical…Abstract Number: 2248 • ACR Convergence 2023
Primary Non-response in Psoriatic Arthritis Treated with Biologics and Targeted Synthetic Therapies in Daily Clinical Practice
Background/Purpose: In Psoriatic arthritis (PsA), patients who fail to respond to biologics and targeted synthetic therapies (ts/bDMARDs), switching to another ts/bDMARD should be considered. Failure…Abstract Number: PP09 • ACR Convergence 2023
Practicing Mindfulness to Improve Quality of Life
Background/Purpose: I’ve been living with symptoms of PSA and fibromyalgia for over 15 years. Four years ago, after flareup that severely impacted my mobility where…Abstract Number: 0161 • ACR Convergence 2023
Differences and Similarities Between the EULAR/ASAS-EULAR Recommendations and National Recommendations for Treatment of Patients with Psoriatic Arthritis and Axial Spondyloarthritis Across Europe
Background/Purpose: National treatment recommendations are often used to optimize patient care and may differ from international recommendations. The aim of this study was to assess…Abstract Number: 0488 • ACR Convergence 2023
Factors Associated with Work Productivity Among Individuals with Psoriatic Arthritis (PsA) and Psoriasis (PsO): The Role of Patient Reported Outcomes and Disease Severity
Background/Purpose: Patients with Psoriatic Arthritis (PsA) and Psoriasis (PsO) have an increased rate of work loss due to their disease compared the general population; however,…Abstract Number: 0504 • ACR Convergence 2023
Burden of Disease of Psoriatic Arthritis in Latin America: A Systemic Review of Literature
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory pathology that generates a substantial and progressive deterioration of functionality and quality of life. It is associated…Abstract Number: 0779 • ACR Convergence 2023
Influence of Sex on the Persistence of Different Classes of Targeted Therapies for Psoriatic Arthritis: A Cohort Study of 14,778 Patients from the French Health Insurance Database (SNDS)
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous condition and sex differences in phenotypic presentation, disease trajectory, and treatment response have been reported. Nevertheless, it remains…Abstract Number: 1396 • ACR Convergence 2023
Comprehensive Evaluation of the Digital Annular Pulleys: From Ultrasonographical to Anatomical and Histological Evaluation with Special Focus on the Entheses
Background/Purpose: The digital annular pulleys (DAP) are anatomical structures of soft connective tissue organized as transverse fibers of variable width, thickness, and configuration that overlay…Abstract Number: 1427 • ACR Convergence 2023
Efficacy of Upadacitinib in Patients with Psoriatic Arthritis Stratified by Involvement of Weight-bearing Joint Regions: A Post Hoc Subgroup Analysis of the Phase 3, Randomized, SELECT-PsA 1 and SELECT-PsA 2 Trials
Background/Purpose: Involvement of weight-bearing joints in patients with PsA can be associated with reduced activities of daily living and quality of life. Upadacitinib (UPA) is…Abstract Number: 1641 • ACR Convergence 2023
The Window of Opportunity in Psoriatic Arthritis: Similar to Rheumatoid Arthritis?
Background/Purpose: In rheumatoid arthritis (RA), initiation of treatment within the window of opportunity, i.e. 12 weeks after symptom onset, results in higher remission rates, and…
- « Previous Page
- 1
- …
- 13
- 14
- 15
- 16
- 17
- …
- 81
- Next Page »